XVPrime™-PRT

An ATP Bioluminomics™ Predictive Residual Toxicity Assay for Ex Vivo Primary Explanted Cells

All assays are available as kits
and contract research services.

To determine the proportion of cells remaining or resistant to drug administration.
To determine whether cells change their sensitivity to a drug after a single dose.
To determine the effect on cells to multiple drug administration.
To determine whether cells exhibit expansion potential after a single drug dose.

In vitro assay that detects whether unaffected cells (residual cells) remain after drug administration.
In vitro assay that indicates changes in drug sensitivity to cells.
The most sensitive of any assay readouts incorporating proven ATP Bioluminomics™ Technology.
Instrument-based, quantitative and fully standardized readout procedure.
Available for adherent or non-adherent cells.
Flexibility to use virtually any in vitro cell protocol, reagents and growth factors/cytokines.
Reliably compare results over time.
Incorporate secondary, re-plating technology.
Multiplexing capability to incorporate flow cytometry and other assay readouts for additional information from the same sample.
Easy to learn, fast to use.

Ex Vivo Primary Explanted Cells from:

General and Specialized Cell Systems from Ex Vivo Primary Explanted Cell Sources:

Please note that for cells of the blood-forming system, HemoGenix® has developed specialized assay platforms. See Related Assays below.

For Research Use Only. Not for clinical diagnostic use.

Plate luminometer or multiparameter plate reader with "glow" luminescence measuring capability.